144 results
Page 2 of 8
8-K
EX-99.2
1rl9a8laj9rlxzu5 4t
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
ez0z715 q7m
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
gfa72qlb26fhup9lr
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
1rwairduuuvzg7
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
EX-99.1
6e1gnssh gnd0i74h69
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
EX-99.2
7jeg0
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
48j a5de2bi
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
EX-1.1
bx5mt
14 Sep 22
Entry into a Material Definitive Agreement
9:01am
424B5
q8m6oagbw6elmdalqqd7
14 Sep 22
Prospectus supplement for primary offering
7:28am
8-K
EX-99.1
eu92ewy1878t 7xy
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
yruwo4c54v x11sj63t
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
gaind29f
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm